Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -12.76% | -18.47% | -9.21% | -7.26% | -0.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.76% | -18.47% | -9.21% | -7.26% | -0.33% |
| Cost of Revenue | 46.21% | 52.84% | 78.13% | 105.98% | 114.42% |
| Gross Profit | -82.97% | -118.18% | -191.87% | -379.37% | -659.67% |
| SG&A Expenses | 24.00% | 25.66% | 33.20% | 33.50% | 27.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.50% | 41.58% | 58.36% | 71.03% | 68.96% |
| Operating Income | -52.79% | -64.96% | -89.68% | -116.25% | -114.30% |
| Income Before Tax | -50.74% | -37.43% | -43.21% | -56.65% | -67.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.74% | -37.43% | -43.21% | -56.65% | -67.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.74% | -37.43% | -43.21% | -56.65% | -67.19% |
| EBIT | -52.79% | -64.96% | -89.68% | -116.25% | -114.30% |
| EBITDA | -53.44% | -66.17% | -92.14% | -120.31% | -118.26% |
| EPS Basic | -26.74% | -14.00% | -8.83% | -15.32% | -3.59% |
| Normalized Basic EPS | -32.39% | -43.70% | -36.42% | -25.32% | -2.22% |
| EPS Diluted | -26.99% | -14.23% | -9.05% | 5.44% | 15.02% |
| Normalized Diluted EPS | -32.39% | -43.70% | -36.42% | -26.87% | -3.42% |
| Average Basic Shares Outstanding | 19.89% | 18.33% | 26.34% | 46.65% | 79.27% |
| Average Diluted Shares Outstanding | 19.89% | 18.33% | 26.34% | 44.84% | 76.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |